S32
VC Fund
San Diego, United States
S32 is a VC fund in San Diego focused on Health Care and Biotechnology. S32 the new venture fund launched by Bill Maris, was named in homage to Section 31, an intelligence agency from the Star Trek universe.Maris, the GV (Google Ventures) founder/former-CEO, has raised $150 million for the project that will focus on various investments.The fund will be run directly by Maris and primarily based out of SanDiego.
- Total investments:
- 177
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries S32 invests in
Stages S32 invests in
Countries S32 invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Investment Focus
Industry
- Health Care 43 (24%)
- Biotechnology 42 (24%)
- Artificial Intelligence 20 (11%)
- Medical 18 (10%)
- Therapeutics 15 (8%)
Stage
- Series B 43 (24%)
- Series A 37 (21%)
- Series C 16 (9%)
- Seed 15 (8%)
- Funding Round 11 (6%)
Country
- United States 83 (47%)
- United Kingdom 3 (2%)
- Israel 2 (1%)
- India 1 (1%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew Harrison
Managing Partner and CEO
|
Managing Partner and CEO | Total investments: 14 | Find email | |
Bill Maris
Founder
|
Founder | Total investments: 24 | Find email | |
Jennifer Kercher
COO and General Counsel
|
COO and General Counsel | Total investments: 0 | Find email | |
Jonathan Faerber
CFO
|
CFO | Total investments: 0 | Find email | |
Lindsey Acharya
Chief of Staff and Executive Assistant
|
Chief of Staff and Executive Assistant | Total investments: 0 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Whatnot
|
Whatnot is a Los Angeles-based startup that creates a place where avid collectors could come together over shared interests. Whatnot is a marketplace to buy and sell authentic collectible items. Whatnot was founded in 2019, in California. | $545M / Series G / Aug 06, 2026 | |
Beacon Biosignals
|
Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $11M / Series B / Apr 06, 2026 | |
Autoscience
|
Autoscience merges science and tech to automate vehicles, improving safety, efficiency, and performance. It integrates AI, robotics, and materials science to transform transportation. | $14M / Seed / Mar 18, 2026 | |
RunSybil
|
RunSybil is an AI-driven offensive security platform that continuously evaluates applications and infrastructure for vulnerabilities. Leveraging cutting-edge AI techniques, it autonomously identifies and exploits real-world security flaws through sophisticated penetration testing. By automating hacker-like intuition, RunSybil delivers proactivedefense capabilities, empowering organizations to strengthen the security of modern applications. | $40M / Seed / Mar 18, 2026 | |
Outtake
|
Outtake provides agentic AI cyber defense through the use of AI agents for automated response, real-time classification, and advanced threat detection. In order to combat fraud and impersonation, it focuses on open-source intelligence, multi-surface anti-phishing, and digital identity protection. | $40M / Series B / Jan 28, 2026 | |
humans&
|
humans& designs and trains AI systems that emphasize human understanding, long-term reasoning, memory, and multi-agent collaboration to support how people and organizations work together. humans& integrates scientific research with applied product development, combining advances in reinforcement learning, behavioral modeling, and alignmentwith practical user interfaces. The organization develops AI technologies intended to strengthen coordination, decision-making, and communication across teams and communities. | $480M / Seed / Jan 20, 2026 | |
Pomelo
|
Pomelo provides a cloud-native financial technology platform that enables businesses to issue, process, and manage payment cards and related services through modular APIs and infrastructure. Its technology supports the issuance and processing of credit, debit, and prepaid cards, including options for businesses without their own issuing licensethrough BIN sponsorship and integration with Mastercard and Visa networks. The company’s platform also includes tools for transaction authorization, chargeback handling, fraud monitoring, tokenization for digital wallets, and logistical support for card production and distribution. Pomelo’s offerings aim to streamline card program development by consolidating technical, regulatory, and operational components into a unified system that can be tailored to diverse use cases across fintech, banking, and embedded finance sectors. It supports virtual and physical card workflows and provides dashboards and management interfaces to monitor and control card portfolios and transactions. The company collaborates with clients to integrate its APIs into existing systems and scale card products across multiple markets. Pomelo’s infrastructure emphasizes flexibility, data visibility, and compliance with international payment standards. | $55M / Series C / Jan 20, 2026 | |
Black Forest Labs
|
Black Forest Labs creates advanced generative deep learning models for images and videos. They focus on making these technologies widely accessible and transparent, ensuring that their innovations are easy to use and understand. This approach aims to democratize access to cutting-edge technology and foster greater trust and utility. | $300M / Series B / Dec 01, 2025 | |
Aspen Neuroscience
|
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $115M / Series C / Nov 20, 2025 | |
|
Beacon Biosignals
|
Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $86M / Series B / Nov 13, 2025 | |
| See all 177 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does S32 invest in?
S32 invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Series B and Series A stage. Most of the 177 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact S32?
Public channels for S32 include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at S32?
The team at S32 includes Andrew Harrison (Managing Partner and CEO), Bill Maris (Founder) and Jennifer Kercher (COO and General Counsel), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
